COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines

Table 4

Variables and outcomes among COVID-19-confirmed patients.

	ICU survivors (n = 9)	ICU nonsurvivors (n = 22)	value (two-tailed)
Demographics
Age (years)	59 (±12)	67 (±12)	0.151
Gender (% of males)	66.7%	54.5%	0.696
SAPS-3	44 (±14.7)	61.6 (±14.3)	0.008
Comorbidities
Neurologic			0.503
Yes	1 (11.1%)	1 (4.5%)
No	8 (88.9%)	21 (95.5%)
Cardiovascular			0.417
Yes	5 (55.6%)	16 (72.7%)
No	4 (44.4%)	6 (27.3%)
Pulmonary			0.642
Yes	1 (11.1%)	5 (22.7%)
No	8 (88.9%)	17 (80.6%)
Renal			1.000
Yes	0	2 (9.1%)
No	9 (100%)	20 (90.9%)
Endocrine			0.433
Yes	3 (33.3%)	12 (54.5%)
No	6 (66.7%)	10 (45.5%)
Autoimmune			0.077
Yes	2 (22.2%)	0
No	7 (77.8%)	22 (100%)
Malignancy			1.000
Yes	0	2 (9.1%)
No	9 (100%)	20 (90.9%)
Laboratories on ICU admission
Hemoglobin (g/L)	134 (±21)	135 (±15)	0.806
WBC count (×10^3/µL)	8.5 (±6.2)	8.4 (±4)	0.997
Platelets (×10^9/L)	259 (±109)	204 (±50)	0.179
PF ratio	201 (±152)	148 (±73)	0.344
Lactate (mmol/L)	1 (±2.5)	2.2 (±2)	0.021
Treatment strategy
Hydroxychloroquine			0.642
Yes	8 (88.9%)	17 (77.3%)
No	1 (11.1%)	5 (22.7%)
Tocilizumab			0.456
Yes	6 (66.7%)	11 (50%)
No	3 (33.3%)	11 (50%)
Lopinavir/ritonavir			0.642
Yes	1 (11.1%)	5 (22.7%)	1
No	8 (88.9%)	17 (77.3%)
CRRT			0.017
Yes	2 (22.2%)	16 (72.7%)
No	7 (77.8%)	6 (27.3%)
NMBA			0.642
Yes	1 (11.1%)	5 (22.7%)
No	8 (88.9%)	17 (77.3%)
Prone positioning			0.696
Yes	3 (33.3%)	10 (45.5%)
No	6 (66.7%)	12 (54.5%)
IVIG			1.000
Yes	1 (11.1%)	2 (9.1%)
No	8 (88.9%)	20 (90.9%)
HA-330			1.000
Yes	2 (22.2%)	6 (27.3%)
No	7 (77.8%)	16 (72.7%)
Intubation			0.077
Yes	7 (77.8%)	22 (100%)
No	2 (22.2%)	0
Others
Number of days intubated	19 (±7)	12 (±6)	0.048